抗EGFR治疗结直肠癌疗效的潜在预测标记精选.pptVIP

* Permission to include this figure in this CCO activity was granted by Sabine Tejpar, MD, PhD. * * FOLFOX4 Patients with previously untreated EGFR-detectable mCRC (N = 237) FOLFOX4 + Cetuximab Van Cutsem E, et al. ASCO 2008. Abstract 2. OPUS Trial FOLFOX ± Cetuximab: Study Schema Patients stratified by region and ECOG performance score Safety population: n = 1202 ITT population: n = 1998 Cetuximab 400 mg/m2 initial dose,  then 250 mg/m2 wkly ITT人群与KRAS不同状态患者疗效数据对比 ITT人群 KRAS野生型患者 KRAS突变型患者 FOLFOX Cetuximab+ FOLFOX FOLFOX Cetuximab + FOLFOX FOLFOX Cetuximab + FOLFO